Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of mitapivat in adults with pyruvate kinase deficiency
NL-OMON52866Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (3 cohorts), sponsored by Agios Pharmaceuticals. Primary endpoint: Long-term safety and tolerability of AG-348. Started Sep 2019; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NL-OMON52866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52866.